New business development in menstrual blood-derived stem cells, cultured products, women’s health femtech, and related areas
First written in FY2023-Q2. . Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3Specified the timing for launching new businesses next fiscal yearAnnual report
「The Company is also actively advancing new businesses toward launching them next fiscal year, including a business for storage customers using products generated through the culturing of umbilical cord blood and umbilical cords, such as exosomes, and a femtech business providing comprehensive support for women’s health in collaboration with major operating companies.」
Regarding new business development, including menstrual-blood-derived stem cells, the Company disclosed plans to advance businesses using cultured products derived from umbilical cord blood and umbilical cords, as well as its femtech business, toward launching them next fiscal year. - FY2023-Q2First statedAnnual report
「Going forward, the company will actively promote new business development, including the development of regenerative medicine using menstrual-blood-derived stem cells as a new cell source, businesses using products from the culture of umbilical cord blood and umbilical cords, and femtech businesses providing comprehensive support for women’s health in cooperation with major operating companies.」
The Company identified stem cells derived from menstrual blood, cultured products derived from umbilical cord blood and umbilical cords, and femtech focused on women’s health as new areas for business development.